Bio-Path Holdings, Inc. (BPTH)

NASDAQ: BPTH · IEX Real-Time Price · USD
3.92
-0.02 (-0.51%)
Aug 18, 2022 3:59 PM EDT - Market closed
-0.51%
Market Cap 28.07M
Revenue (ttm) n/a
Net Income (ttm) -12.55M
Shares Out 7.16M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,756
Open 3.91
Previous Close 3.94
Day's Range 3.91 - 4.00
52-Week Range 2.68 - 8.62
Beta 1.48
Analysts Buy
Price Target 11.22 (+186.2%)
Earnings Date Aug 16, 2022

About BPTH

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing... [Read more...]

Industry Biotechnology
Founded 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol BPTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BPTH stock is "Buy." The 12-month stock price forecast is 11.22, which is an increase of 186.22% from the latest price.

Price Target
$11.22
(186.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bio-Path Holdings Reports Second Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf...

Bio-Path Holdings Reports First Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfo...

Why Bio-Path Holdings Shares Are Rising After Hours

Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research Annu...

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers

Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

Seasoned Communications Leader Brings Significant Industry Expertise Seasoned Communications Leader Brings Significant Industry Expertise

Bio-Path Holdings Reports Full Year 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop ...

Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology An...

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf...

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a port...

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexig...

Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Triple Negative Breast Cancer Phase 1/1b Clinical Tri...

Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients.

BPTH Stock: The Good News That Has BioPath Investors Smiling Today

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today ap...

BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Tha...

Why Bio-Path Holdings Shares Are Surging Higher Today

Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 i...

Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?

The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b trial, si...

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute...

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Pro...

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf...

Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today

Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc. (NASDAQ: VTVT) are among the biggest biotech movers Tuesday. Moderna Gains On Additional EU Orders: Moderna...

Other symbols: MRNAVTVT